Stryker

Stryker shares rose approximately 2% today, extending recent gains driven by momentum surrounding the full market release of its Mako RPS robotic platform for knee and shoulder procedures. Recent research highlights how the Mako RPS commercial ramp could reshape the bull case, with analysts suggesting the stock may trade 15% below fair value as adoption accelerates. Q1 2026 revenue reached $6.02 billion (+2.63% YoY), though operating income contracted 5.21% YoY, signaling margin pressure from manufacturing and mix headwinds. The stock has declined 3.29% year-to-date and currently trades 16.68% below its 52-week peak of $404.14, though it remains well above its 60-day moving average of $311.29. The steep PE ratio of 38.69 embeds substantial expectations for Mako's future contribution to earnings. Offsetting this optimism, procedure volume declines reported by major hospital systems including HCA Healthcare in Q2 have weighed on the broader medtech sector and create near-term revenue headwinds.

Stryker extended its upside momentum today with a 3.15% gain, advancing to $330.25 and notably outperforming its peer group, largely driven by the full market release of Mako RPS handheld knee robotics which is expected to expand the company's footprint in robot-assisted orthopedic procedures. Earnings dynamics remain solid with Q1 2026 EPS of $1.93 (up 14.2% YoY) and net profit of $745 million (up 13.91% YoY), underpinning operational momentum. On valuation and positioning, while year-to-date performance remains underwater at -5.15%, the stock has recovered 17.53% from its 52-week low and trades modestly above its 20-day moving average of $322.92. However, the elevated P/E multiple of 37.94 and lukewarm Q1 revenue growth of just 2.63% suggest that current market pricing already embeds fairly optimistic expectations around the company's growth trajectory.

Stryker shares extended gains today, rising 3.21% during regular trading to $318.97, then surging further to $326 in after-hours trading for a total daily gain exceeding 5%, primarily driven by the full market release of its Mako RPS robotic-assisted spinal surgery platform. The medtech sector had faced headwinds from HCA Healthcare's weak Q2 surgical volumes, though recent trading signals a sector rebound. The company's Q1 results showed revenues of $6.02 billion with modest 2.63% YoY growth, EPS of $1.93 up 14.2% YoY, operating income down 5.21% YoY, yet net margins held steady at 12.38%. Positioning-wise, Stryker remains down 8.39% year-to-date but has recovered 13.51% from its May trough of $281, trading 21.22% below its 52-week high of $404.87. Wells Fargo's maintained Buy rating provides underlying support for investor confidence.

Stryker's stock fell 1.70% today, primarily pressured by profit-taking following a pre-market rally and persistent weakness in downstream customer demand. In intraday trading, the stock surged to $321 during pre-market hours before reversing course to close at $309.24 during regular trading, reflecting market hesitancy about the company's growth trajectory. The key headwind stems from HCA Healthcare's second-quarter surgery volume decline, and as a major healthcare provider customer, its softer demand directly impacts surgical equipment suppliers like Stryker, which triggered a 5%+ single-day decline in mid-July. On the positive side, the company completed full market release of its Mako robotic surgery platform expansion. From a valuation perspective, the stock has retreated 23.62% from its one-year peak of $404.87, now trading below its 20-day moving average of $321.95 and approaching the 60-day MA of $310.95. Recent earnings showed Q1 revenue of $6.02 billion with only 2.63% year-over-year growth, marking a significant slowdown.

Stryker declined 1.4% to $314.58, displaying a stark reversal pattern after surging to $330.576 in pre-market trading at 04:01 ET before collapsing through the regular session to $311.58 at 09:45 ET. The weakness reflects ongoing pressure from HCA Healthcare's mid-July Q2 surgery volume disappointment, which weighed on the entire medical device sector. The stock has now retreated 22.3% from its 52-week high of $404.87 and trails 9.65% year-to-date. Underlying operations remain solid with Q1 revenue growth of 2.63%, EPS rising 14.2% to $1.93, and completion of the full market release for the Mako RPS robotics system; Wells Fargo maintains a buy rating. However, at a 36.14 forward PE multiple and lacking near-term catalysts, the stock faces pressure despite fundamental stability.